How to Get Rezdiffra (Resmetirom) in Texas

The direct answer

Resmetirom is available to Texas patients the same way most specialty drugs are: through a licensed Texas prescriber who documents fibrosis stage, an insurer prior authorization process, and a specialty (or, for some patients, a 503A compounding) pharmacy that dispenses or ships within the state. There is no separate "Texas approval" process for a federally approved drug. What varies by state and by plan is the prior authorization paperwork, Medicaid coverage, and pharmacy logistics, not the underlying FDA label. Because those variable pieces (insurer rules, formulary tiers, pharmacy networks, and cash prices) change over time, they need to be reverified at the point of care rather than treated as fixed facts from any single article.

What resmetirom is approved to treat, and what it is not

The FDA approved resmetirom in March 2024 for adults with MASH and moderate-to-advanced fibrosis (F2-F3), to be used with diet and exercise. It is not approved as a general fatty liver or weight-loss drug, and it is not approved for decompensated cirrhosis. The prescribing information available on the FDA's site is the authoritative source for the approved indication, dosing, contraindications, and monitoring requirements, and should be the reference point for any Texas prescriber or patient (https://www.accessdata.fda.gov/).

Updated global consensus guidance on MASLD/MASH risk stratification and treatment initiation emphasizes that pharmacotherapy decisions should follow confirmed fibrosis staging rather than clinical suspicion alone, and that response should be monitored with a defined follow-up plan rather than assumed (https://pubmed.ncbi.nlm.nih.gov/41950980/). This is the same standard Texas prescribers are expected to apply: fibrosis stage first, then treatment, then monitoring.

What the pivotal trial showed, and its limits

Resmetirom's approval rested on a phase 3 trial (MAESTRO-NASH) that used liver biopsy to assess fibrosis improvement and NASH resolution at 52 weeks, comparing resmetirom against placebo in patients with biopsy-confirmed disease. The trial reported that a meaningfully larger share of resmetirom-treated patients achieved fibrosis improvement without worsening of NASH, and a larger share achieved NASH resolution, than placebo-treated patients. Readers who want the exact percentages, confidence intervals, and safety signals should consult the original NEJM publication directly rather than relying on any secondhand summary, because precise trial numbers are easy to misquote and this draft did not have a verified copy of that paper to cite with confidence.

What the trial does not establish: long-term outcomes beyond the trial period, effects on liver-related mortality or transplant-free survival, or performance in patients with decompensated cirrhosis, who were excluded. Fibrosis improvement on biopsy is a surrogate endpoint; it correlates with but is not the same as a clinical outcome like reduced liver failure.

Who can prescribe Rezdiffra in Texas

Physicians (MD/DO), nurse practitioners, and physician assistants can all prescribe resmetirom in Texas within their scope of practice. Texas nurse practitioners gain independent prescriptive authority after completing the state's required collaborative practice period; physician assistants prescribe under a physician delegation agreement. In practice, prescriptions most often originate with hepatologists, gastroenterologists, or endocrinologists who have ready access to fibrosis staging tools, though primary care clinicians can prescribe if they obtain and document appropriate staging (liver biopsy, FibroScan/vibration-controlled transient elastography, or a validated non-invasive score such as FIB-4 combined with enhanced liver fibrosis testing).

Academic medical centers and community gastroenterology and hepatology practices across major Texas metro areas increasingly manage MASH patients on resmetirom, but which specific institutions have a standing protocol changes over time and should be confirmed by calling the practice rather than assumed from a general list.

Telehealth access in Texas

Texas telemedicine rules (22 TAC §174, administered by the Texas Medical Board) permit prescribing through audiovisual encounters once a legitimate provider-patient relationship is established (https://www.tmb.state.tx.us/). This means a Texas-licensed telehealth prescriber can write a resmetirom prescription without an in-person visit, provided the patient already has, or can obtain, the fibrosis documentation the prescriber needs to confirm eligibility.

In practice, telehealth works best for patients who already have FibroScan or biopsy results in hand. Patients without existing fibrosis documentation typically need an in-person elastography appointment before a telehealth prescriber can complete the diagnostic picture. Appointment wait times for hepatology telehealth versus in-person specialist visits vary by platform, region, and season; specific day-ranges are not something this article can state reliably, and patients should ask directly when scheduling.

Labs and imaging before starting

Before initiating resmetirom, prescribers typically confirm the diagnosis and screen for contraindications with:

Diagnostic confirmation (one of):

• Liver biopsy showing NASH with fibrosis stage F2 or F3, or
• Non-invasive staging (FibroScan liver stiffness and controlled attenuation parameter, or a validated non-invasive score) consistent with at least F2 fibrosis, combined with elevated ALT and metabolic risk factors

Safety labs:

• Comprehensive metabolic panel including AST, ALT, albumin, bilirubin, platelets
• Thyroid function testing, since resmetirom acts on a thyroid hormone receptor pathway even though it is designed to be liver-selective
• Lipid panel (LDL reduction is an expected on-treatment effect)
• Complete blood count
• INR/PT if cirrhosis is suspected

Conditions to rule out or flag:

• Decompensated cirrhosis
• Active hepatitis B or C infection
• Concurrent use of drugs that strongly inhibit the same metabolic pathway resmetirom depends on

The FDA-approved prescribing information is the authoritative source for the exact monitoring schedule and drug interaction list, and Texas prescribers should be working from the current label rather than a secondhand summary (https://www.accessdata.fda.gov/).

Insurance and prior authorization in Texas

Most commercial insurers require prior authorization before covering resmetirom. The documentation typically requested includes a confirmed MASH diagnosis, non-invasive or biopsy-based evidence of F2-F3 fibrosis, documentation that lifestyle modification was attempted, relevant metabolic labs, and a prescriber attestation of fibrosis stage.

Texas Medicaid: as of this writing, Texas Medicaid does not cover resmetirom for MASH as a standalone indication; coverage pathways that exist are tied to comorbid conditions such as type 2 diabetes rather than MASH alone. This is a state Medicaid formulary rule, which changes over time, so it should be confirmed directly with the Texas Health and Human Services Medicaid formulary or the patient's managed care organization before a patient is told coverage is or is not available.

Medicare Part D and commercial plans: coverage tier, coinsurance percentage, and prior authorization turnaround time vary by plan and change from year to year. This article does not have a verified, current source for specific coinsurance percentages or turnaround-day estimates, so readers should get those numbers directly from their plan's formulary documents rather than from any general article, including this one.

Manufacturer support: Madrigal Pharmaceuticals has described a patient support program intended to help eligible patients with access and affordability; eligibility rules and copay amounts change and should be confirmed on the manufacturer's current program page rather than assumed from a prior year's terms.

Pharmacy access: specialty and 503A compounding

Branded Rezdiffra distributes through a limited specialty pharmacy network rather than typical retail pharmacies. Specialty pharmacies generally handle prior authorization coordination and shipping logistics; which specific national chains are in-network for a given patient depends on their insurance plan and changes over time, so the specific pharmacy name should come from the prescriber or insurer, not from a general list.

Texas-licensed 503A compounding pharmacies operate under Texas State Board of Pharmacy oversight and USP 795 non-sterile compounding standards (https://www.pharmacy.texas.gov). A 503A pharmacy may be able to compound resmetirom for a patient with a specific formulation need, such as a swallowing difficulty or an excipient allergy, pursuant to an individual prescription. A compounded preparation is not the FDA-approved product, has not gone through the same manufacturing and bioequivalence review, and should only be used with the prescribing physician's explicit understanding and documentation of that difference.

Cost without insurance

Resmetirom is an expensive specialty drug, and the wholesale acquisition cost reported around the time of its 2024 launch was in the tens of thousands of dollars annually. Because list prices, copay assistance terms, and cash-pay compounding costs all change over time, this article intentionally does not restate a specific dollar figure as current fact. Patients facing a cash-pay situation should ask the prescriber's office or the manufacturer's patient support program for the current list price and any assistance program terms, and should ask a 503A pharmacy directly for its current compounding price if considering that route.

Clinical trial enrollment is another potential cost-avoidance path for eligible patients; current resmetirom-related trials, including any enrolling in Texas, can be searched directly at clinicaltrials.gov rather than assumed from a static list, since trial recruitment status changes frequently.

Transferring a prescription to Texas

Texas pharmacies can generally accept a valid prescription transferred from another state, provided the original prescriber's license was active and the receiving Texas pharmacy verifies validity. Prior authorization approvals, however, are tied to a specific insurance plan and do not transfer between states; a patient moving to Texas will need to re-initiate prior authorization with their Texas-based plan. Patients relocating should have their prior hepatologist or prescriber send fibrosis staging records to a new Texas-based provider who can take over prescribing and monitoring.

Ongoing monitoring

Once a patient starts resmetirom, monitoring generally includes periodic liver chemistry checks, a lipid panel to track the expected LDL reduction, and a plan to reassess fibrosis status (via non-invasive testing or, less commonly in routine practice, repeat biopsy) after roughly a year of treatment to judge whether therapy is providing measurable benefit. The exact monitoring intervals in the FDA label are the authoritative reference (https://www.accessdata.fda.gov/); updated consensus guidance on MASLD treatment monitoring likewise stresses defining a response-assessment timepoint in advance rather than continuing therapy indefinitely without reassessment (https://pubmed.ncbi.nlm.nih.gov/41950980/).

Cardiometabolic risk, including lipid changes on treatment, is relevant beyond the liver: emerging literature on MASLD and cardiovascular risk describes shared mechanisms between liver fibrosis progression and cardiovascular disease, which is part of why lipid monitoring is built into routine follow-up rather than treated as an isolated lab value (https://pubmed.ncbi.nlm.nih.gov/42541628/).

What is established, what is plausible, and what is not established

Established: Resmetirom is FDA-approved for MASH with F2-F3 fibrosis; a Texas-licensed MD, DO, NP, or PA can prescribe it; Texas permits telehealth prescribing under a valid provider-patient relationship; 503A compounding pharmacies in Texas operate under Texas State Board of Pharmacy oversight; Texas Medicaid, as of this writing, does not cover resmetirom for MASH alone.

Plausible but not confirmed in this review: Specific wait-time ranges for telehealth versus in-person hepatology appointments in Texas; specific prior authorization turnaround times by insurer; specific delivery timelines from named specialty pharmacies; whether particular named academic centers currently have a standing resmetirom protocol.

Not established: Long-term clinical outcome data (mortality, transplant-free survival) beyond the surrogate fibrosis endpoints studied in the pivotal trial; safety and efficacy in decompensated cirrhosis, where the drug is not indicated; equivalence of compounded resmetirom to the branded product.

If a patient or clinician needs a number this article marks as unverified, such as a current copay tier, a specific plan's turnaround time, or a current cash price, the right next step is to get it directly from the insurer, the specialty pharmacy, or the manufacturer's program page, dated to the day it was checked.

Verification checklist: stable facts versus facts you must reconfirm

Use this before advising a patient or acting on anything in this article.

Stable facts (federal or clinical, unlikely to change quickly, but still confirm the source is current):

• FDA-approved indication is MASH with F2-F3 fibrosis, with diet and exercise (verify against current FDA label, not a summary)
• Resmetirom is a THR-β selective agonist, oral, once daily
• Texas allows MD, DO, NP, and PA prescribing within scope of practice
• Texas Medical Board telemedicine rules (22 TAC §174) permit prescribing via audiovisual encounter with a valid provider relationship
• Texas State Board of Pharmacy licenses and inspects 503A compounding pharmacies under USP 795
• A compounded preparation is legally and pharmacologically distinct from the FDA-approved branded product

Date-sensitive facts (reconfirm at the time of care, and note the date you checked):

• Current Texas Medicaid formulary status for resmetirom, checked directly with HHSC or the patient's MCO
• This specific commercial or Part D plan's prior authorization criteria and turnaround time
• Current formulary tier and coinsurance/copay amount for this plan
• Manufacturer patient assistance program eligibility rules and current terms
• In-network specialty pharmacy for this patient's plan, and its current shipping timeline
• Current 503A compounding pharmacy cash price, if compounding is being considered
• Current wholesale acquisition cost / list price, from the manufacturer or FDA label update, not a prior year's figure
• Whether a specific academic center or practice currently has an active resmetirom prescribing protocol
• Any open clinical trials for resmetirom, checked directly at clinicaltrials.gov

If an answer to a date-sensitive item cannot be confirmed at the point of care, treat it as unknown rather than filling it in from this or any other general article.